Business Wire

Mobileum Enables GSMA Industry Services’ Launch of VOLTIS 5G Extension, Streamlining Global 5G Roaming Verification

26.2.2026 09:00:00 CET | Business Wire | Press release

Share

New framework reduces bilateral testing complexity and accelerates time-to-market for next-generation roaming services

Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced its expanded role in enabling GSMA Industry Services’ launch of the VOLTIS (Voice over LTE Interoperability & Testing Service) 5G Extension Verification Program. The new extended program goes beyond the existing VoLTE/IMS verification framework to include 5G readiness verification, providing operators with a standardized path to validate next-generation roaming and interoperability.

As an appointed verification partner, Mobileum manages the end-to-end validation process, from test planning and resource validation through test execution, troubleshooting, and final reporting, delivering a streamlined, globally recognized verification experience for operators worldwide.

As 5G roaming scales globally, operators face increased complexity in validating VoLTE and 5G interoperability across international partners. The VOLTIS 5G Extension offers a standardized verification path that helps operators reduce reliance on bilateral testing, strengthen service reliability, and gain formal industry recognition. Operators can more quickly form roaming partnerships and launch services with greater confidence.

GSMA Industry Services, part of the wider global mobile industry association, provides device, network and verification services to over 2,200 customers, including mobile operators and device manufacturers.

“As operators transition to 5G, roaming interoperability becomes significantly more complex and business-critical,” stated Miguel Carames, Chief Product Officer at Mobileum. “We are excited to continue partnering with GSMA Industry Services to extend the VOLTIS program to include 5G. We believe it is critical for the industry to provide a standardized global verification path that removes friction from bilateral testing and enables operators to validate and deploy 5G roaming faster to enable transformational roaming experiences at a global scale.”

“The expansion of the VOLTIS Testing Program to include 5G readiness marks a significant step forward in strengthening end‑to‑end interoperability across the global mobile ecosystem,” stated Tyler Smith, Head of Industry Services at GSMA. “By providing a consistent and trusted framework under the GSMA Interoperability services umbrella, we are helping operators, vendors, and device manufacturers reduce testing friction, enhance service reliability, and accelerate the rollout of dependable next‑generation capabilities across all markets.”

According to GSMA Intelligence, 5G connections are forecast to reach 5.6 billion by 2030 (5G in Context, Q3 2025, Nov,2025), with 65% operating on standalone networks. At the same time, Kaleido Intelligence projects that combined wholesale and retail roaming revenues will exceed $50 billion in 2027, driven by rapid growth in 5G roaming and IoT connectivity.

As roaming traffic increases and operators sunset legacy networks, ensuring voice continuity and seamless cross-border performance becomes essential. Without proper testing and verification, operators risk roaming failures, degraded user experience, interoperability issues, customer churn, and delays in launching international partnerships.

Mobileum brings decades of experience supporting global roaming, interoperability testing, and network validation across voice, messaging, and data services. Through its roaming analytics, active testing, and signaling intelligence solutions, Mobileum helps operators assure service performance, protect roaming revenues, and accelerate the launch of new international partnerships.

The VOLTIS Verification Program and its 5G Extension are available globally to support operators across all regions.

For more details on GSMA Interoperability testing, please visit this link.

About Mobileum Inc.

Mobileum is a leading provider of Telecom analytics solutions for roaming, core network, security, risk management, domestic and international connectivity testing, and customer intelligence. More than 1,000 customers rely on its Active Intelligence platform, which provides advanced analytics solutions, allowing customers to connect deep network and operational intelligence with real-time actions that increase revenue, improve customer experience, and reduce costs. Headquartered in Silicon Valley, Mobileum has global offices in Australia, Germany, Greece, India, Japan, Portugal, Singapore, UK, and United Arab Emirates. Learn more at www.mobileum.com

About GSMA

The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry, and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Services and Solutions, and Outreach. This activity includes advancing policy, tackling today’s biggest societal challenges, underpinning the technology and interoperability that make mobile work, and providing the world’s largest platform to convene the mobile ecosystem at the MWC and M360 series of events.

Find out more at www.gsma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226635756/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye